COMPLETEDPHASE2

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

NCT00507169•Salvat

Summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria

•Pregnant and breastfeeding women
•Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Key Dates

Start Date

September 1, 2006

Primary Completion Date

September 1, 2007

Completion Date

September 1, 2007

Last Updated

June 8, 2011

Conditions

Overactive Bladder (OAB)

Interventions

SVT-40776

DRUG

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07193407

Overactive Bladder (OAB)

View study

RECRUITINGNA

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07195656

Overactive Bladder (OAB)

View study

ENROLLING_BY_INVITATIONNA

Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

NCT06765629

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 8, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Overactive Bladder (OAB)

View study

NOT_YET_RECRUITINGPHASE2